To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had ...

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her ...

James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young ...

The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of ...

Stephen D. Klyce, PhD, FARVO, is an adjunct professor of ophthalmology at the Icahn School of Medicine at Mount Sinai in Port Washington, NY. Klyce is a research scientist involved in developing ...

As ophthalmic technology continues to advance, new diagnostic and surgical devices are redefining precision, efficiency, and ...

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient ...

The Phase 2 OptimUM-09 trial shows promising results for uveal melanoma, addressing the lack of approved systemic therapies.

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.